GlassScriptPhysician profile
Chadwick W Hatfield
NPI 1780714931
$13,030.56
in general payments reported to CMS, 2019-2025
47 companies · $3,014 in 2025
The $3,014 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,148 · 2020: $568 · 2021: $1,311 · 2022: $1,688 · 2023: $2,357 · 2024: $2,945 · 2025: $3,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,273 · Education: $41.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,273.22 |
| Education | $41.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,479.86 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,174.58 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Janssen Biotech, INC. | $1,026.60 | 2021-2025 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $953.56 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $682.69 | 2019-2025 | |
| Qol Medical, LLC | $590.01 | 2019-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $418.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $412.34 | 2022-2025 | |
| Ardelyx, INC. | $390.85 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $351.34 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $312.49 | 2022-2025 | Dupixent |
| Daiichi Sankyo INC. | $308.05 | 2019-2025 | Injectafer |
| Celgene Corporation | $275.32 | 2021-2024 | Zeposia |
| Organon LLC | $231.87 | 2022-2025 | Renflexis, Hadlima |
| Gilead Sciences, INC. | $212.63 | 2019-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $205.67 | 2019-2024 | Linzess |
| Amgen INC. | $167.51 | 2020-2023 | Amjevita, Avsola |
| Nestle Healthcare Nutrition INC. | $156.86 | 2021-2023 | |
| Celltrion USA INC. | $156.17 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Biotissue Holdings INC. | $150.13 | 2023 | |
| Ferring Pharmaceuticals INC. | $143.72 | 2023-2025 | Rebyota |
| Allergan, INC. | $139.31 | 2019-2020 | |
| Braintree Laboratories, INC. | $132.65 | 2020-2025 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $119.71 | 2020-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $118.16 | 2023-2025 | Voquezna |
| Novo Nordisk INC | $97.57 | 2025 | |
| Pharmacosmos Therapeutics INC. | $80.53 | 2024-2025 | Monoferric |
| Evoke Pharma, INC. | $62.63 | 2023-2024 | Gimoti |
| Redhill Biopharma INC. | $62.58 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Intercept Pharmaceuticals, INC. | $53.79 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $45.45 | 2024-2025 | Vowst |
| Alfasigma USA, INC. | $41.81 | 2020-2021 | |
| Lucid Diagnostics INC. | $38.95 | 2022-2023 | |
| Medtronic, INC. | $30.03 | 2025 | Interstim |
| Axonics, INC. | $21.93 | 2024 | Axonics |
| Alnylam Pharmaceuticals INC. | $21.39 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.01 | 2023 | Austedo Xr |
| Ipsen Biopharmaceuticals, INC | $17.50 | 2025 | Iqirvo |
| Ucb, INC. | $16.74 | 2020 | |
| Ethicon US, LLC | $16.56 | 2025 | Linx Reflux Management System |
| Shire North American Group INC | $16.48 | 2019 | |
| Janssen Scientific Affairs, LLC | $15.35 | 2023 | |
| Shionogi INC | $15.23 | 2020 | |
| Echosens North America, INC. | $13.24 | 2024 | Fibroscan |
| Dova Pharmaceuticals | $11.66 | 2019 | |
| Acacia Pharma INC | $11.50 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chadwick Hatfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.